CSF-HC Otic Powder Drug Recalled for Manufacturing Deviations
Edge Pharma, LLC is recalling CSF-HC Otic Insufflation Capsule nationwide due to Current Good Manufacturing Practice (CGMP) deviations. The recall affects 440 cartons of this antibiotic and steroid combination powder.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for CGMP deviations, a manufacturing/quality control issue. The source text does not report any illnesses, injuries, or hospitalizations. Class II recalls without reported adverse events and without high-risk pathogens or allergen issues typically fall in the Moderate range.
Plain-English summary
Edge Pharma, LLC is recalling CSF-HC Otic Insufflation Capsule, containing Sulfacetamide Sodium/Ciprofloxacin/Hydrocortisone/Amphotericin B Otic Powder (50mg/30mg/25mg/5mg), distributed nationwide. The product is supplied in 5-count bottles, NDC 05446-1634-01, with a total of 440 cartons affected.
The recall was initiated on December 6, 2021, and classified as a Class II recall on January 24, 2022. The reason for recall is Current Good Manufacturing Practice (CGMP) deviations identified by the manufacturer. This is a voluntary, firm-initiated recall announced via press release.
Consumers who have this product should stop using it and contact their healthcare provider. Patients currently using this medication should consult with their physician before discontinuing use or switching to an alternative treatment.
The recalled product
- Product
- CSF-HC Otic Insufflation Capsule, Sulfacetamide Sodium/Ciprofloxacin/Hydrocortisone/Amphotericin B Otic Powder, 50mg/ 30mg/ 25mg/ 5mg, 5 count bottle, Edge Pharma, LLC, 856 Hercules Dr., Colchester, VT 05446, NDC 05446-1634-01
- Manufacturer
- Edge Pharma, LLC
- Category
- Drug — Otic / Ear Medication
- Affected units
- 440
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 10-2021-05@9 01-01-2022 & 10-2021-28@4 01-26-2022
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 56 recalled by Edge Pharma, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 56 products in this recall →Related recalls
Same manufacturer · Edge Pharma, LLC
See all →- ModerateDibutyl Squaric Acid Topical Solution Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2022-02-02
- ModerateProfound-PE Dental Gel Recalled for Manufacturing Deviations
FDA (Drugs) · 2022-02-02
- SevereMVASI Sterile Ophthalmic Solution Lacks Assured Sterility
FDA (Drugs) · 2022-02-02
- SevereVancomycin HCl Injection Recalled for Sterility Assurance Issues
FDA (Drugs) · 2022-02-02
- ModerateLET Topical Gel drug recall for CGMP deviations
FDA (Drugs) · 2022-02-02
Same hazard · manufacturing deviation
See all →- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06